ArticleInternational journal of molecular sciences2025
Orientin Reverses Premature Senescence in Equine Adipose Stromal Cells Affected by Equine Metabolic Syndrome Through Oxidative Stress Modulation.
Article in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Programmed cell death in metabolic syndrome: From molecular mechanisms to therapeutic strategies (Review).International journal of molecular medicine · 2026Review
- Oxygen Variations, 2nd Edition: Integrative Insights from Cellular Models to Clinical Physiology.International journal of molecular sciences · 2026Article
- Orientin and Cancer Suppression: Molecular Mechanisms and Synergistic Effects.Journal of Cancer · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Equine metabolic syndrome (EMS) is a prevalent endocrine disorder associated with insulin dysregulation, oxidative stress, and impaired regenerative capacity of adipose-derived stem cells (ASCs). The aim of this study was to evaluate the effects of orientin-a plant-derived flavonoid with known antioxidant properties-on equine ASCs (EqASCs) derived from both clinically healthy and diagnosed EMS-affected mares. EqASCs were treated with orientin to evaluate its biological effects. The analysis included key cellular functions such as proliferative capacity, viability, apoptosis, oxidative stress, senescence, clonogenicity, and migration. Orientin significantly enhanced the proliferative activity of EqASCs, as evidenced by increased Ki67 expression and favorable alterations in cell cycle distribution. In addition, the treatment improved overall cell viability, reduced apoptotic activity, and restored both the clonogenic potential and migratory capacity of the cells, with particularly pronounced effects observed in EqASCs isolated from EMS-affected horses. Importantly, orientin also led to a marked reduction in cellular senescence and oxidative stress, further suggesting its potential as a protective and regenerative agent in metabolically impaired ASCs. These findings indicate that orientin can exert comprehensive cytoprotective effects on EqASCs, with pronounced benefits in cells derived from EMS-affected animals. By improving multiple functional parameters, orientin emerges as a promising candidate for therapeutic strategies aimed at restoring the regenerative potential of ASCs compromised by metabolic dysregulation in horses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.